Any HER2 Ever? If a tumor ever read 1 + or 2 +, that’s good enough for Dr. Cairo, regardless of a later zero. Reporting variability, she argues, explains the flip-flop, and the DB-04 data back treating the historical stain. FacebookXRedditPinterestEmail You may also like Video Dr. Jason Mouabbi & Dr. Michelina Cairo – Talking DB04 and DB06 2 min read Video Concurrent Endocrine: Old-School? 1 min read Video DB-04 to DB-06, the Steps of Ultra-Low 1 min read Video Ultra-Low in Real Life 1 min read Video Capecitabine Comfort vs ADC Leap 1 min read Video First-Strike 1 min read Recommended Videos DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia 4 months ago Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan 4 months ago New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed 4 months ago Cleopatra, DESTINY-Breast09 & What Comes Next – Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse 4 months ago
Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan 4 months ago
New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed 4 months ago
Cleopatra, DESTINY-Breast09 & What Comes Next – Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse 4 months ago